Novartis business deals across mergers & acquisitions, business development & licensing were summarized for investors at 2024 J.P. Morgan Healthcare conference.

This video highlights the scale and strategic focus of over $6bn of deals in 2023 by our CEO Vas Narasimhan. It provides examples of how our we are strengthening portfolios and how AI advancements in drug development moves are creating a stronger company for the future.

*This video uses audio from the webcasted event.*
J.P. Morgan Healthcare Conference
Event Date: January 08, 2024
Full webcast here: https://go.novartis.social/49012mq
Full presentation here: https://go.novartis.social/3SzISTc
Novartis JPM HC 2024 Coverage: https://go.novartis.social/48T3StR
Investor Relations: https://go.novartis.social/3SCtnKp
Investor Events: https://go.novartis.social/3vWoP8M
Novartis Strategy: https://go.novartis.social/42iv0jr

Disclaimer: J.P. Morgan Healthcare Conference live event contains forwardlooking statements. Such forwardlooking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: https://go.novartis.social/3SzISTc

The J.P. Morgan Healthcare conference live event also contains nonIFRS measures. An explanation of nonIFRS measures can be found on our website https://go.novartis.social/4bk6cM3.

Learn more: https://go.novartis.social/48T3StR